Browse Studies — Arctuva

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies

Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and mo…

B-cell MalignancyMarginal Zone LymphomaFollicular Lymphoma+6 more

Estimated

~$10 – $7,500

BeOne MedicinesNCT05006716

Phase 1

Phase 1 Study of Lonitoclax (ZE50-0134) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Select Low-grade Lymphomas

This Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of l…

CLL / SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)+2 more

Estimated

~$10 – $8,750

Lomond Therapeutics Holdings, Inc.NCT06708897

Phase 1

A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies

This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase…

Relapsed/Refractory Hematological MalignanciesRelapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLLRelapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)+4 more

Estimated

~$10 – $8,750

Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM)…

Waldenström MacroglobulinemiaLymphoplasmacytic LymphomaB-Cell Lymphoproliferative Disorder+1 more

Estimated

~$10 – $7,500

Shayna Sarosiek, MDNCT06986174